Search

shutterstock_2261453831(1) (1)

Announcements

Announcements

HOMEWhat’s NewAnnouncements

2020.Aug.25

TFDA clearance for Phase 1 clinical study for Novel Botulinum Toxin, OBI-858

2020.Aug.03

Announcement on the change of representative of corporate director

2020.Jul.31

Announcement on resignation of Audit Committee Member

2020.Jul.31

Announcement on resignation of Compensation Committee Member

2020.Jul.31

Announcement on resignation of independent director

2020.Jul.29

TFDA clearance of passive immunotherapeutic monoclonal antibody OBI-888 for phase I/II human clinical studies

2020.Jul.22

Change in Phase III clinical study design for OBI-822 targeting TNBC and will continue the study with new clinical study design

2020.Jul.13

Resignation of representative of corporate director

2020.Jun.29

OBI filled application of Phase 1 human clinical study for active immunotherapeutic cancer vaccine, OBI-866, to TFDA

2020.Jun.23

Supplementary statements on news article

News

Latest News

Events

Latest events